Here is the design of a clinical trial:

Official Title: The Study on the Clinical Value of Fufang E'Jiao Jiang Intervening Cancer-related Fatigue (Deficiency of Qi and Blood)

Included conditions:
- Cancer-related Fatigue

Study Armgroups:
- {'label': 'Treatment group', 'type': 'EXPERIMENTAL', 'description': "Fufang E'Jiao Jiang, 20milliliters(mL) once, 3 times a day, continuous intervention for 21days each cycle, and use 2 cycles", 'interventionNames': ["Drug: Fufang E'Jiao Jiang"]}
- {'label': 'control group', 'type': 'PLACEBO_COMPARATOR', 'description': "Placebo containing low-dose Fufang E'Jiao Jiang, 20mL once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles", 'interventionNames': ["Drug: placebo containing low-dose fufang E'Jiao Jiang"]}

Interventions:
- {'type': 'DRUG', 'name': "Fufang E'Jiao Jiang", 'description': "Fufang E'Jiao Jiang, 20milliliters(mL) once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles", 'armGroupLabels': ['Treatment group'], 'otherNames': ['A listed Chinese Medicine']}
- {'type': 'DRUG', 'name': "placebo containing low-dose fufang E'Jiao Jiang", 'description': "placebo containing low-dose Fufang E'Jiao Jiang, 20mL once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles", 'armGroupLabels': ['control group'], 'otherNames': ['placebo']}

Primary Outcomes:
- {'measure': 'Fatigue degree with the Piper fatigue scale (Piper)', 'description': 'Piper is composed of 24 questions assessing total CRF, as well as subscales of behavioral, affective, sensory, and cognitive/mood fatigue. Each question is cored from 0 to10 points, where a higher score indicates severe symptoms; 1 to 3 point is mild, 4 to 6 point is moderate, and 7 to 10 point is severe. Piper is taken at the baseline, 1 weeks, 3 weeks,4 weeks, and 6 weeks after treatment', 'timeFrame': '6 weeks'}

Please estimate the sample size based on the assumption: 
Using a 0.05 significance level, 90% power, and considering a 20% dropout rate.
Sample Size
        The sample size calculation was based on a meta-analysis that was conducted. According to the meta-analysis, following the change in RPFS-CV score before and after TCM intervention, the mean and standard deviation of RPFS-CV were 3.2âÂ±â1.9 and 4.2âÂ±â1.9 for the experimental group and the placebo group.
38
 For this study, the sample size was calculated based on the mean change in RPFS-CV score for CRF measured in 3 different cancer types. Using a 0.05 significance level, 90% power, it was determined that 77 cases were needed for each group of 3 different cancer types, as shown in Figure 2, according to the sample size calculation using 2 sample T-Test power analysis with PASS software. We defined the final sample size as 600 for all 3 different cancer type subgroups in consideration of 20% of the participants who may drop out and be lost to follow-up.
        
          Figure 2.
          
            Two-sample T-test power analysis.